Topics of discussion:
Q 6 week pembrolizumab dosing schedule FDA approved
Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28)
The monarcHER study of abemaciclib in HER+ MBC (12:20)
The GRIFFIN study of Dara+VRD in myeloma (17:00)
